Navigation Links
Growth in Drug Sales of the Top 10 Pharmaceutical Companies Slowed to its Lowest Level in Years in 2008
Date:5/12/2009

Pharma's Premier Quantitative Company and Drug Evaluation Tool Designed Specifically for Business Development Available Now with a New User-Friendly Interface

Productview Plus from Decision Resources Includes Data for Over 1000 Drugs Across 147 Product Classes

WALTHAM, Mass., May 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the growth in drug sales of the top 10 pharmaceutical companies slowed to its lowest level in years in 2008 -- growing just 3.7 percent compared to 7.9 percent the year before. The performance of the top 10 companies in the U.S. market, the world's largest, was particularly poor, with sales down 3.5 percent year-over-year.

"This trend is expected to continue in the U.S. with growth in the top 10 companies forecasted to remain flat out to 2015 despite the contribution of recently seen large-scale acquisitions by Pfizer, Roche and Merck & Co.," said Stephan Gauldie Ph.D., Director at Decision Resources. "Of the top 10 pharma companies, only Roche is expected to post a compound annual growth rate above the 3 percent that is forecasted for the overall U.S. market out to 2015."

These data come from the newly updated Productview Plus, the pharmaceutical industry's premier quantitative company and drug evaluation tool designed specifically for business development. The new Productview Plus allows business planners and new product commercialization managers to quickly assess forecasts and evaluate market scenarios that will determine a company's/drug's success or failure.

"By manipulating the data by brand, therapeutic area, drug class and company, users can track market sizes, assess barriers to market entry, quickly benchmark internal forecasts or analyze the potential of licensing candidates," continued Dr. Gauldie.

Based on company reported sales, Productview Plus includes data for 1,100 ethical drugs from over 110 companies and across 147 product classes. Productview Plus provides five years of historical sales as well as a seven-year forecast for all drugs, split by United States and Rest of World regions -- allowing users to get a universal understanding of a company's/drug's current and future position.

Productview Plus is available now from Decision Resources.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Elizabeth Marshall
    Decision Resources
    781-296-2563
    emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Actuaries: Addressing Health Spending Growth is Path to Sustainable Health Care System
2. Covance To Present at Bairds 2009 Growth Stock Conference
3. Milestone Scientific Reports Strong Sales Growth in First Quarter 2009 Results
4. Nicotine May Help Prevent Damage from Bioterrosim Toxin and Growth Factors in Heart Disease News from Molecular Medicine
5. AMN Healthcare Services to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference and at the Robert W. Baird 2009 Growth Stock Conference
6. Adolescent Growth Plate Injuries May Be Related to Overuse
7. Despite the Economic Downturn, Long-Term Growth Potential in the US Dental Biomaterial Market Remains Robust
8. Process controlling T cell growth and production identified
9. Injured Marines at Risk for Abnormal Bone Growth
10. Injured Marines at risk for abnormal bone growth
11. Genoptix Reports Strong Growth for the First Quarter of 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Nevada (PRWEB) , ... October 13, 2017 , ... ... Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil ... required and providing a CBD form that can be easily incorporated into liquid products, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that ... insurance companies have a waiver for care if the client has a cognitive impairment ... family pays for care, is often waived, so the benefits from their insurance start ...
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/19/2017)... Sept. 19, 2017   ZirMed Inc ., a recognized ... announced that it has been ranked #1 by its users ... Rankings 2017 User Survey. ZirMed was recognized as the ... hospitals and medical centers over 200 beds and holds one ... technology user survey history. ...
Breaking Medicine Technology: